The expected outcome of this proposal is a novel care pathway delivered by pharmacists to improve side effects during oral chemotherapy for patients, a known barrier to adherence, and ultimately to prevent progression and early mortality. Our long-term goal for P3OC is to develop and test new dashboard features to optimize pharmacy care, meet future needs for value-based payment models, and improve patient outcomes.
No guidelines or interventions for patients and their family caregivers exist to support patient adherence to a new medication (venetoclax) and their quality of life. Our research team seeks to understand the real experience and care needs of patients and their family caregivers with the new AML treatment. With the information we learn from this study, we will be able to develop an effective support program for patients with AML and their family caregivers to manage their symptoms at home and improve their quality of life.
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Collecting data on chronic GVHD instances
The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].
Purpose:This is a two-arm preliminary efficacy RCT in 120 participants testing a 6-week home-based walking and progressive resistance exercise program (EXCAP©®) vs. standard care on CIPN, interoception, and inflammation. Participants: This study will enroll 120 participants receiving neurotoxic chemotherapy or have completed neurotoxic chemotherapy in the past nine months (i.e., taxane-, platinum-, vinca alkaloid-, epothilone-, or proteasome inhibitor-based chemotherapy). Procedures (methods): Participants will complete questionnaires, clinical assessments, and a blood draw at two time points: pre-intervention (week 0, T1) and post-intervention (approximately week 6, T2).
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
